Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
Paola Guglielmelli, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Chiara Maccari, Barbara Mora, Elisa Rumi, Ana Triguero, Maria Chiara Finazzi, Helna Pettersson, Chiara Paoli, Francesco Mannelli, Daniele Vanni, Alessandro Rambaldi, Francesco Passamonti, Alberto Álvarez‐Larrán, Björn Andréasson, Alessandro M. Vannucchi, Tiziano Barbui
Abstract
Survival in patients with myelofibrosis (MF), median overall survival (OS) of 6 to 7 years, is shorter than that of the general population.1 MF is also associated with profound negative effects on quality of life.
Topics & Concepts
RuxolitinibMyelofibrosisMedicineInternal medicineOncologyIntensive care medicineBone marrowMyeloproliferative Neoplasms: Diagnosis and TreatmentKruppel-like factors researchChronic Myeloid Leukemia Treatments